
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax SA's obefazimod has demonstrated strong efficacy and safety profiles in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, reinforcing the drug's potential for significant market penetration. The data highlights that both tested doses met regulatory endpoints, prompting an increase in peak sales estimates and penetration rates from 20% to 22%. Additionally, the favorable performance of obefazimod in patients with prior treatment failures enhances its competitive advantage and underscores the drug's promising financial outlook.
Bears say
Abivax SA's stock outlook is negatively impacted by the company's ongoing history of financial losses, indicating a lack of profitability and solid operational foundation. The low success bar set by previous oral therapies highlights concerns regarding the efficacy of its drug candidate obefazimod, which may struggle to establish a competitive edge in the market. Furthermore, uncertainties surrounding potential partnerships for commercialization could jeopardize the launch success and overall financial viability of the company.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares